Peter Foley to Humans
This is a "connection" page, showing publications Peter Foley has written about Humans.
Connection Strength
0.104
-
Foley PJ. Effect of low carbohydrate diets on insulin resistance and the metabolic syndrome. Curr Opin Endocrinol Diabetes Obes. 2021 10 01; 28(5):463-468.
Score: 0.028
-
Foley PJT, Gunson JTS, Baumann SL. Two Stories about Diet and Diabetes in Europe. Nurs Sci Q. 2020 01; 33(1):85-90.
Score: 0.025
-
Foley P, Stockfleth E, Peris K, Basset-Seguin N, Cerio R, Antonio Sanches J, Guillen C, Farrington E, Lebwohl M. Adherence to topical therapies in actinic keratosis: A literature review. J Dermatolog Treat. 2016 Nov; 27(6):538-545.
Score: 0.019
-
Lebwohl M, Gooderham MJ, Warren RB, Tha?i D, Foley P, Gottlieb AB, Torres T, Popmihajlov Z, Jou YM, Linaberry M, Daamen C, Griffiths CEM. Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis. Clin Exp Dermatol. 2025 Sep 25; 50(10):2030-2036.
Score: 0.009
-
Strober B, Blauvelt A, Warren RB, Papp KA, Armstrong AW, Gordon KB, Morita A, Alexis AF, Lebwohl M, Foley P, Kisa RM, Colston E, Wang T, Banerjee S, Tha?i D. Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52?weeks from two phase 3 trials (POETYK PSO-1 and PSO-2). J Eur Acad Dermatol Venereol. 2024 Aug; 38(8):1543-1554.
Score: 0.008
-
Strober B, Tada Y, Mrowietz U, Lebwohl M, Foley P, Langley RG, Warren RB, Wang M, Vanvoorden V, Szilagyi B, Ciaravino V, Paul C. Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial. Br J Dermatol. 2023 05 24; 188(6):749-759.
Score: 0.008
-
De Bruin-Weller M, Deleuran M, Biedermann T, Bissonnette R, Foley P, Girolomoni G, Hercogov? J, Hong CH, Katoh N, Pink A, Richard MA, Shumack S, Silvestre JF, Thyssen JP, Weidinger S. The Treat-to-Target Project in Atopic Dermatitis: One Year On. Acta Derm Venereol. 2023 Apr 21; 103:adv5382.
Score: 0.008